Media Centre
-
Vemurafenib Receives Approval for Metastatic Melanoma
August 19, 2011
The FDA approved the melanoma drug vemurafenib along with a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine.
-
Sarah Cannon Research Institute Names Director and Executive Director of Its Drug Development Program
June 02, 2011
NASHVILLE, TN, June 2, 2011 – Sarah Cannon Research Institute (SCRI) has promoted Jeffrey R. Infante, M.D., to Director, Drug Development for the Nashville based program where he previously served as associate director. Howard A. “Skip” Burris III, M.D., chief medical officer for the organization, will assume the role of executive director for the overall drug development initiative.
-
American Society of Clinical Oncology (ASCO) Accepted 52 Sarah Cannon Research Institute Abstracts for Presentation at 2011 Annual Meeting
June 01, 2011
NASHVILLE, TN – June 1, 2011 – The American Society of Clinical Oncology (ASCO) has selected 52 abstracts by Sarah Cannon Research Institute (SCRI) for presentation at the 2011 ASCO Annual Meeting, the premier educational and scientific oncology conference, which takes place June 3-7 in Chicago.
-
Yale Cancer Center, Smilow Cancer Hospital, and Sarah Cannon Research Institute Announce Intent to Collaborate Scientifically to Advance Cancer Research
June 01, 2011
CHICAGO, IL, June 1, 2011 – Sarah Cannon Research Institute (SCRI) today announced an intention to collaborate scientifically with Yale Cancer Center (YCC) and Smilow Cancer Hospital at Yale-New Haven (SCH) to advance cancer research. A formal agreement will follow in the coming weeks.
-
Sarah Cannon Research UK is now actively enrolling patients on clinical trials
April 04, 2011
-
SARAH CANNON RESEARCH INSTITUTE (SCRI) TO PRESENT AT AACR 102ND ANNUAL MEETING
April 02, 2011
Inhibiting two prominent pathways activated in cancer cells appears encouraging in a clinical study • Combination therapy targets MEK and PI3K pathways • Phase I trials of single agent MEK and PI3K pathway inhibitors alone have shown signs of anti-tumor activity • Abstract to be presented at AACR meeting on Sunday, April 3
-
New study calls for annual mammograms
December 01, 2010
With numerous conflicting reports on the importance of yearly breast exams, Dr. Freya Schnabel weighs in on women, age and mammograms.
-
Screening ALL women for breast cancer at 40 'will save thousands of lives'
December 01, 2010
All women should be screened for breast cancer from the age of 40, leading doctors say.
-
Yearly Breast Cancer Scan After Age 40 Lowers Mastectomy Rates
December 01, 2010
A new study that was presented today at the Radiological Society of North America (RSNA), concluded that women who have an annual mammogram between the ages of 40 and 50, significantly reduce the risk of mastectomy after breast cancer.
-
RSNA: Annual Mammogram May Reduce Mastectomy Risk
December 01, 2010
Screening among women between 40 and 50 tied to lower mastectomy risk after breast cancer
-
Mammograms for 40-somethings 'would save 1,000 a year'
November 30, 2010
Prof Kefah Mokbel and colleagues at the London Breast Institute, a private clinic, are calling for changes to the NHS Breast Screening Programme, which currently offers women aged 50 to 70 one mammogram every three years.
-
Vital Signs
October 05, 2010
Sarah Cannon Research Institute quietly opened up shop in London this summer. The Nashville-based business — like a growing number of its local peers — sees enough international growth potential to warrant committing capital.